Brokerages Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Target Price at $5.80

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have earned a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $5.17.

SGMO has been the topic of several recent analyst reports. Truist Financial decreased their target price on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. StockNews.com cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Wells Fargo & Company dropped their target price on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 31st. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research note on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research note on Monday, January 27th.

Sangamo Therapeutics Price Performance

Shares of SGMO stock opened at $0.85 on Friday. Sangamo Therapeutics has a one year low of $0.30 and a one year high of $3.18. The company’s fifty day moving average price is $1.09 and its 200-day moving average price is $1.41. The company has a market capitalization of $176.54 million, a price-to-earnings ratio of -1.13 and a beta of 1.49.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The business had revenue of $7.55 million for the quarter, compared to the consensus estimate of $11.70 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. Equities research analysts expect that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Institutional Trading of Sangamo Therapeutics

Hedge funds have recently made changes to their positions in the business. E Fund Management Co. Ltd. bought a new stake in Sangamo Therapeutics during the fourth quarter worth approximately $25,000. JPMorgan Chase & Co. boosted its holdings in shares of Sangamo Therapeutics by 679.5% in the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 21,793 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Sangamo Therapeutics by 2,319.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 25,000 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in Sangamo Therapeutics during the 4th quarter valued at $28,000. Finally, Shelton Wealth Management LLC bought a new stake in Sangamo Therapeutics in the fourth quarter worth $29,000. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.